SCHEMBL6780377

SCHEMBL6780377

Cn1cnc2c1c(=O)n(CCCC(O)CO)c(=O)n2C

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 7/20 0.62
TNF P01375 4/20 0.62
PDE4A P27815 2/20 0.62
PDE4B Q07343 2/20 0.62
PDE4C Q08493 2/20 0.62
PDE4D Q08499 2/20 0.62
USP2 O75604 1/20 0.62
LMNA P02545 1/20 0.62
CYP1A2 P05177 1/20 0.62
TSHR P16473 1/20 0.62
NFKB1 P19838 1/20 0.62
ACHE P22303 1/20 0.62
PMP22 Q01453 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
RXFP1 Q9HBX9 1/20 0.62
CHIT1 Q13231 1/20 0.57
CHIA Q9BZP6 1/20 0.57
GLA P06280 1/20 0.54
BLM P54132 1/20 0.54
ADORA2A P29274 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7284106 0.96 ADORA2B (0.65) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL9293971 0.96 ADORA2B (0.65) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6777335 0.95 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6778845 0.95 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6780531 0.95 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6779319 0.95 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6779694 0.95 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL8017364 0.95 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6774347 0.95 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6774042 0.95 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693105-B1 USING XANTHINYL DERIVATIVES TO REDUCE TREATMENT INDUCED TOXICITY; INHIBITING CELLULAR SIGNALING THROUGH SECOND MESSENGER PATHWAY; REDUCING CELLULAR LEVEL OF NONARACHI-DONATE PHOSPHATIDIC ACID AND DIACYLGLYCEROL CELL THERAPEUTICS, INC. 2004-02-17 US disclosed
US-6133274-A TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS CELL THERAPEUTICS, INC. (US) 2000-10-17 US disclosed
US-6121270-A N-(EPOXYALKYL)XANTHINE DERIVATIVES WHICH MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI CELL THERAPEUTICS, INC. (US) 2000-09-19 US disclosed
US-5866576-A COMPOUNDS THAT ACT AS DRUGS ON THE CELLULAR AND BIOCHEMICAL LEVEL TO MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI. CELL THERAPEUTICS, INC. (US) 1999-02-02 US disclosed
US-5780476-A ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS CELL THERAPEUTICS, INC. (US) 1998-07-14 US disclosed
EP-0662834-A4 NOVEL EPOXIDE-CONTAINING COMPOUNDS. CELL THERAPEUTICS INC (US) 1996-04-17 EP disclosed
EP-0669825-A4 HYDROXYL-CONTAINING COMPOUNDS. CELL THERAPEUTICS INC (US) 1996-04-03 EP disclosed
EP-0669825-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1995-09-06 EP disclosed
EP-0662834-A1 NOVEL EPOXIDE-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1995-07-19 EP disclosed
WO-1994011001-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-05-26 WO disclosed
WO-1994006431-A1 NOVEL EPOXIDE-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-03-31 WO disclosed